TABLE 2.
Clinical and outcome characteristics
| Clinical data | N | (%) | Treatment/outcome | (%) | |
|---|---|---|---|---|---|
| Gender | Acute treatment | ||||
| Female | 16 | (76) | Anticoagulation | 3 | (15) |
| Male | 5 | (24) | MP pulse | 15 | (75) |
| Age (range, years) | 50 (22–86) | IVIG | 4 | (20) | |
| Autoimmunity | PLEX | 3 | (15) | ||
| New onset | 17 | (81) | Long‐term IS treatment | 3 | (15) |
| Exacerbation | 4 | (19) | |||
| Additional prior AD | 5 | (24) | Clinical outcome | ||
| Familial AD predisposition | 7 | (33) | Median f/u, (range, days) | 49 (20–105) | |
| Prior IS | 4 | (19) | PD | 0 | (0) |
| Median intervals | SD | 1 | (5) | ||
| To symptoms (range, days) | 11 (3–23) | PR | 15 | (71) | |
| To admission (range, days) | 17 (5–42) | CR | 5 | (24) |
Abbreviations: AD, autoimmune diseases; CR, complete remission; f/u, follow‐up; IS, immunosuppression; IVIG, intravenous immunoglobulins; MP, methylprednisolone; N, number; PD, progressive disease; PLEX, plasma exchange; PR, partial remission; SD, stable disease.